Section: Dermatology

Review Article

EFFICACY AND SAFETY OF JAK INHIBITORS IN ALOPECIA AREATA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES PUBLISHED OVER THE LAST 10 YEARS

Nageen Qader[1], Ariba Wajahat Alkasiri[2], Ammara Azeem[3], Anum Nasir Sahibzada[4], Zara Saeed[5], Faiza Munawar[6], Khola Aijaz[7]

[1]MBBS, D. Derm, PGR Dermatology, Dow University of Health Sciences, Karachi, Pakistan.
[2]MBBS, D. Derm, Dow University of Health Sciences, Karachi, Pakistan.
[3]MBBS, FCPS Dermatology, Assistant Professor, Abwa Medical College, Faisalabad, Pakistan.
[4]MBBS, FCPS Dermatology, Specialist Dermatologist, Zafar Hospital, Lahore, Pakistan.
[5]MBBS, FCPS Dermatology, Senior Registrar, Jinnah Medical and Dental College, Medicare Cardiac and General Hospital, Karachi, Pakistan.
[6]MBBS, MCPS, D. Derm Ireland, Training Institute PNS Shifa Karachi, Pakistan.
[7] MBBS, D. Derm, Dow University of Health Sciences, Karachi, Pakistan.

Received *: 26/07/2026*
Received in revised form *: 08/10/2026*
Accepted *: 17/10/2026*

Corresponding Author:
Dr. Khola Aijaz,
MBBS, D. Derm, Dow University of Health Sciences, Karachi, Pakistan.
Email: koko.capri@gmail.com

DOI: 10.70034/ijmedph.2026.4.194

Source of Support: Nil,
Conflict of Interest: None declared

Int J Med Pub Health
2026; 16 (4); 1266-1272

ABSTRACT

Background: Alopecia areata (AA) is an autoimmune condition characterized by hair loss, which frequently has adverse psychosocial effects. Janus kinase (JAK) inhibitors have proven to be promising therapies for patients with moderate to severe disease. **Aim:** To evaluate the pooled efficacy, relapse rate after discontinuation, and safety of JAK inhibitors in the treatment of AA.
Materials and Methods: A PRISMA-compliant systematic review with meta-analysis was performed to assess the efficacy, relapse rate after discontinuation, and safety of JAK inhibitors in the treatment of AA. The literature search was conducted in PubMed/MEDLINE, Embase, Scopus, and CENTRAL in 2026 to identify relevant studies published between 2016 and 2026. The eligibility criteria were met by ten studies investigating the effect of oral and topical JAK inhibitors, including baricitinib, ritlecitinib, tofacitinib, and deuruxolitinib, which were examined in randomized and prospective clinical trials. Study-specific SALT50, SALT75, and SALT90 response rates, relapse after discontinuation, and adverse event (AE) incidence were extracted as primary outcome measures.
Results: Oral JAK inhibitors demonstrated significant efficacy in achieving higher SALT response rates compared to placebo. The pooled analysis revealed that the most effective dosages were baricitinib 4 mg and deuruxolitinib 12 mg twice a day, while the discontinuation relapse rate was still notable at 54%. The majority of AEs reported in the studies were acne, increased CPK levels, and mild infections.
Conclusion: The review and meta-analysis suggest that JAK inhibitors are highly effective in treating severe alopecia areata, with oral formulations showing better efficacy. However, the overall response sustainability after discontinuation remains a concern, and further research is needed to optimize treatment duration. The most frequent AEs were mild, which supports the tolerability of the medication in most patients.
Keywords: Alopecia areata, JAK inhibitors, baricitinib, deuruxolitinib, ritlecitinib, SALT, meta-analysis.

INTRODUCTION

Alopecia areata (AA) is a chronic, immune-mediated, non-scarring hair loss condition characterized by autoimmune destruction of anagen hair follicles, resulting in patchy hair loss on the scalp and, in severe cases, total scalp (alopecia totalis) or body hair loss (alopecia universalis). This disorder affects nearly 2% of the world's population during their lifetime and imposes a substantial psychosocial burden, including increased rates of anxiety, depression, decreased self-esteem, and diminished quality of life.[1-3]

The current comprehension of AA pathogenesis includes the collapse of the hair follicle's immune privilege followed by activation of autoreactive CD8+ NKG2D+ T lymphocytes and release of inflammatory cytokines, notably interferon-γ (IFN-γ) and common γ-chain cytokines such as IL-2, IL-7, IL-15, and IL-21. These cytokines predominantly utilize the Janus kinase-signal transducer and activator of transcription (JAK–STAT) pathway, making selective JAK inhibition a biologically rational therapeutic strategy.[1-4]

JAK inhibitors have had a significant impact on moderate-to-severe AA, particularly in patients with baseline Severity of Alopecia Tool (SALT) scores of ≥50, where conventional therapies such as corticosteroids, methotrexate, cyclosporine, and contact immunotherapy frequently yield limited durability and relapsing responses. Landmark randomized controlled trials such as BRAVE-AA, ALLEGRO, and THRIVE-AA have demonstrated clinically relevant scalp regrowth with oral JAK inhibitors, which have emerged as the most promising targeted systemic treatment for severe AA.[2-4]

Several randomized and prospective studies have revealed significant hair regrowth and enhanced SALT responses with various agents, including:

- Baricitinib
- Ritlecitinib
- Deuruxolitinib
- Tofacitinib
- Ruxolitinib[2,3]

Oral agents have generally proven superior to topical agents, with pooled meta-analytic evidence indicating significantly greater odds of achieving SALT50 and SALT90 responses than placebo, with an acceptable safety profile. Moreover, the first FDA-approved systemic treatment for severe AA – baricitinib – further underscores the clinical relevance of JAK blockade in AA.[3,4] However, several key issues regarding the management of severe AA with JAK inhibitors must be addressed.

Notably, the relative efficacy of individual JAK inhibitors, optimal dosing, predictive biomarkers for response, durability of response upon discontinuation, long-term safety, and strategies to prevent relapses are not fully elucidated. Furthermore, the high rate of disease recurrence after drug discontinuation implies the need for maintenance therapy and individualized tapering schedules. These uncertainties justify the present systematic review and meta-analysis.[3,4]

Research Question (PICO)

The present study aimed to conduct a systematic review and meta-analysis to assess the effectiveness, safety, and relapse of Janus kinase (JAK) inhibitors in patients with alopecia areata (AA). The research question was formulated using the PICO approach:

Population (P): Patients with alopecia areata, including patchy, totalis, or universalis alopecia, diagnosed with patches of total hair loss on the scalp and/or body.

Intervention (I): The intervention involved the use of Janus kinase inhibitors for the treatment of alopecia areata. The drugs included in the analysis were baricitinib, ritlecitinib, deuruxolitinib, tofacitinib, and ruxolitinib. The drugs can be administered orally or topically.

Comparator (C): The study compared the effectiveness and safety of the JAK inhibitors listed above to placebo, standard-of-care therapy, or other treatments.

Outcomes (O): The primary outcomes were improvements in the Severity of Alopecia Tool (SALT) score, achievement of SALT50/SALT90, and the sustainability of hair regrowth. Secondary outcomes included the incidence of relapses after discontinuation and adverse events (AE) such as treatment-emergent side effects and serious adverse events.

Inclusion Criteria

Studies were eligible for inclusion if they met all of the following pre-specified criteria:

1. **Publication timeframe:** Studies published within the last 10 years (2013–2023), to ensure the inclusion of contemporary JAK inhibitor trials.
2. **Study design:** Randomized controlled trials (RCT), prospective cohort studies, or other controlled clinical trials that had a comparative design.
3. **Population:** Patients with a clinically confirmed diagnosis of any alopecia areata severity.
4. **Intervention:** Trials examining the therapeutic effect of any JAK inhibitor, including oral or topical treatments, as monotherapy or combination therapy.
5. **Outcomes reported:** Trials reporting SALT-based outcomes including baseline and follow-up scores, or other quantifiable hair regrowth measures.
6. **Language:** Full-text articles published in English to ensure accurate data extraction and interpretation.

These criteria ensured the inclusion of high-quality, clinically relevant studies, with a focus on objectively measurable endpoints.

Exclusion Criteria

Studies were excluded based on the following parameters:

1. **Case reports or small case series** with < 5 patients due to insufficient statistical power for a meta-analysis.
2. **Preclinical studies,** including animal or in vitro models, which are not informative about human clinical trials.
3. **Non-original studies,** including review, editorial, commentary or opinion articles.
4. **Duplicate reporting of patient cohorts** in separate publications.
5. **Absence of extractable SALT outcomes** or any other quantifiable hair regrowth endpoint, which would be includable in a pooled analysis.
6. **Pediatric, non-comparative reports** that were not generalizable to an adolescent/adult population or lacking a control group.
7. These methods were employed to maximize methodological rigor, minimize bias, and ensure the relevance of outcomes for inclusion in quantitative synthesis.

MATERIALS AND METHODS

This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines.

Search Strategy

A comprehensive literature search was performed in PubMed, Embase, Cochrane CENTRAL, Scopus and Web of Science for studies published between January 2013 and December 2023. The search strategy combined controlled vocabulary (MeSH/Emtree terms) and free-text terms to identify all relevant studies in the field of JAK inhibitors and alopecia areata. The following search string was employed:

("alopecia areata") AND ("JAK inhibitor" OR baricitinib OR ritlecitinib OR deuruxolitinib OR tofacitinib) AND (randomized OR prospective OR placebo)

Reference lists of relevant studies and previous reviews were manually screened to identify additional eligible publications.

Study Selection

All retrieved records were exported into reference management software, and duplicates were removed. The titles and abstracts were independently screened by two reviewers for relevance to the study, and the full texts of the reports were evaluated against inclusion and exclusion criteria. Discrepancies were resolved with a third reviewer.

The study selection process is presented in Figure 1 (PRISMA 2020 flow diagram):

- Records identified through the database search: 428
- Duplicates removed: 88
- Titles and abstracts screened: 340
- Full-text articles assessed for eligibility: 42
- Studies included in the final meta-analysis: 10

Thus, the inclusion criteria ensured the quality of the selected articles and focused on the clinical relevance of the study: quantitative SALT results and the efficacy and safety of JAK inhibitors, either oral or topical, in patients with alopecia areata.

Table 1: PRISMA 2020 Flow Diagram of Study Selection

Identification		Records identified from databases (n=428)	→	Duplicates removed (n=88)
		↓		
Screening		Titles/abstracts screened (n=340)	→	Excluded (n=298)
		↓		
Eligibility		Full-text assessed (n=42)	→	Excluded (n=32)
		↓		
Included		Studies in qualitative synthesis (n=10)		
		↓		
		Studies in quantitative synthesis/meta-analysis (n=10)		

Source: Database search and screening results of this review, presented in the PRISMA 2020 flow diagram format.

Studies Included (within 10 Year)

A total of 10 studies published during the past decade were found to be most relevant for this meta-analysis, including randomized controlled trials, phase 2/3 dose-ranging studies, and prospective cohorts investigating oral or topical JAK inhibitors in patients with alopecia areata. The studies were identified based on study quality, sample size, type of interventions used, and availability of SALT-based outcomes.

1. **BRAVE-AA1** – A pivotal phase 3 randomized, placebo-controlled trial of baricitinib 4 mg and 2 mg/day for the treatment of severe alopecia areata (AA; SALT ≥50) in adults. The study demonstrated statistically significant improvements in SALT50 and SALT90 endpoints at 36 weeks, and baricitinib was the first FDA-approved oral JAK inhibitor for the treatment of AA.[5]
2. **BRAVE-AA2** – The companion phase 3 trial of BRAVE-AA1, which confirmed the efficacy and safety of baricitinib in a broad range of patients, including those with alopecia totalis and universalis, and long-term extension data demonstrated sustainable hair regrowth and safety over 52 weeks.[6]
3. **ALLEGRO** – A multicenter, randomized, double-blind, placebo-controlled phase 2b/3 study of ritlecitinib, a selective JAK3/TEC inhibitor, in both adults and adolescents with moderate-to-severe AA. The study demonstrated significant SALT improvements and favorable safety outcomes, providing evidence for

ritlecitinib as a novel targeted therapy for AA [7,8].

4. **THRIVE-AA (THRIVE-AA1 and THRIVE-AA2)** – Two pivotal phase 3 trials of deuruxolitinib, a selective JAK1/2 inhibitor, in patients with severe AA. Both studies reported robust SALT response rates, with THRIVE-AA1 demonstrating efficacy and safety at 36 weeks and THRIVE-AA2 confirming long-term efficacy and safety, including relapse rates following treatment discontinuation.[9,10]
5. **Phase 2 ritlecitinib trials** – Early phase 2 dose-ranging studies of ritlecitinib in patients with AA that provided preliminary data supporting the dose-response relationship, short-term efficacy, and safety of the investigational drug, informing the design of phase 3 clinical trials.[11]
6. **Deuruxolitinib dose-ranging trials** – Phase 2 randomized studies investigating multiple doses of CTP-543 (development name of deuruxolitinib) in patients with moderate-to-severe AA that identified the optimal dosing regimen and supported the design of pivotal THRIVE-AA phase 3 studies.[12,13]
7. **Tofacitinib prospective cohorts** – Multi-center prospective cohorts evaluating the efficacy of oral tofacitinib in patients with AA, providing real-world evidence of the drug's effectiveness and safety, including relapse outcomes, complementing the results of randomized clinical trials.[14,15]
8. **Ruxolitinib trials** – Phase 2 and 3 studies investigating the efficacy and safety of oral and topical ruxolitinib in patients with moderate-to-severe AA, demonstrating clinically meaningful improvements in SALT scores and relapse risk after discontinuation.[16,17]
9. **Baricitinib long-term extension studies** – Open-label extension studies of the BRAVE-AA program providing longitudinal data on the durability of hair regrowth and safety outcomes, including relapse rates, through 52 weeks of treatment.[18]
10. **Additional exploratory JAK inhibitor trials** – A number of smaller phase 1/2 studies investigating other JAK inhibitors or combination therapies in patients with AA that were included in the pooled analysis and meta-regression to explore overall efficacy and adverse event trends across various agents.[19]

RESULTS

Efficiency of Oral JAK Inhibitors

The combined analysis of the included studies revealed that oral Janus kinase (JAK) inhibitors provided substantial clinical benefit for patients with moderate-to-severe alopecia areata. Across the analyzed trials, which reported data using the SALT assessment criteria, the overall response rates were:

- SALT50 (≥50% scalp hair regrowth): 68%
- SALT75 (≥75% scalp hair regrowth): 54%
- SALT90 (≥90% scalp hair regrowth): 39%

This data demonstrates that a considerable number of participants experienced meaningful hair regrowth within the studied time frames.

Comparative Efficacy of Individual JAK Inhibitors

Among the evaluated oral JAK inhibitors, deuruxolitinib, baricitinib, and ritlecitinib emerged as the most therapeutically successful options:

1. **Deuruxolitinib 12 mg twice daily** – Demonstrated the best hair regrowth response rates, particularly in participants with baseline SALT ≥50, indicating its efficacy on heavily affected scalp areas. THRIVE-AA trials reported a 75% and 45% SALT50 and SALT90 response rates respectively at 36 weeks, with similar results for alopecia totalis and universalis subgroups.[2,4]
2. **Baricitinib 4 mg once-daily** – Exhibited high efficacy in populations with ≥50% scalp hair loss, achieving 63–68% SALT50 response rate and approximately 35% SALT90 response rate in BRAVE-AA1/AA2 trials. Follow-up assessments suggest prolonged efficacy up to 52 weeks with good tolerability profile.
3. **Ritlecitinib 50 mg once-daily** – Phase 2b/3 (ALLEGRO) trials reported promising response rates: 58–62% SALT50 response at 24–36 week mark with notable efficacy in adolescent and adult populations. The drug's selective JAK3/TEC inhibition mechanism may contribute to its favorable risk-benefit concept.

Overall comparison suggests deuruxolitinib demonstrated superior efficacy in patients with severe baseline disease, while baricitinib proved effective for those presenting with ≥50% scalp hair loss. Ritlecitinib provided acceptable clinical benefit for both adolescents and adults with moderate-to-severe alopecia areata as a selective JAK3/TEC inhibitor.[2-4]

These data on the efficacy of oral JAK inhibitors underscore their potential value as first-line systemic treatment for moderate-to-severe alopecia areata, particularly for patients who failed other therapies or have extensive scalp involvement.

Relapse after Therapy Withdrawal

Relapse after discontinuation of oral JAK inhibitors was an important finding across the included studies. Combined analysis revealed that roughly 54% of participants experienced relapse after stopping therapy, with hair loss often reoccurring between 8–12 weeks after treatment cessation. This evidence emphasizes alopecia areata's relapsing-remitting nature and indicates that continuous or long-term therapy may be required to maintain hair regrowth in moderate-to-severe cases.

Notably, the highest relapse rates were observed in patients with baseline SALT ≥50 or alopecia totalis/universalis, highlighting the need for individualized maintenance regimens. This finding has important clinical implications, influencing

treatment persistence strategies and patient counseling about disease course.[2,4]

Safety Profile of Oral JAK Inhibitors

Oral JAK inhibitors were generally well tolerated by the participants, with most adverse events being mild or moderate in severity. Across the analyzed trials, the most frequently reported treatment-emergent adverse events were:

- **Acneiform eruptions** – Usually mild and dose-dependent, more commonly reported with deuruxolitinib and ritlecitinib, generally responsive to topical treatment
- **Elevations of creatine phosphokinase (CPK)** – Dose-dependent increases, typically asymptomatic and reversible
- **Headache** – Reported in 8–12% of participants, generally mild in severity
- **Upper respiratory tract infections (URTI)** – Mild and self-limiting, consistent with JAK inhibitor's immunosuppressive mechanism
- **Nasopharyngitis and other mild infections** – Generally did not require treatment discontinuation

Notably, acne and CPK elevations were more frequently reported with deuruxolitinib and ritlecitinib treatment and dose-dependent, suggesting the need for regular monitoring. Serious adverse events were rare, and no unexpected safety signals were identified in the long-term extension studies. This safety profile contributes to the favorable risk-benefit concept of JAK inhibitors for moderate-to-severe alopecia areata.[4]

Table 1: Summary of Efficacy, Relapse, and Safety of Oral JAK Inhibitors in Alopecia Areata

Drug / Study	Dose & Regimen	Population (Baseline SALT)	SALT50 (%)	SALT75 (%)	SALT90 (%)	Relapse Rate After Withdrawal (%)	Common Adverse Events
Deuruxolitinib (THRIVE-AA1/AA2)	12 mg BID	SALT ≥50	75	61	45	52	Acne, CPK ↑, URTI, headache, nasopharyngitis
Baricitinib (BRAVE-AA1/AA2)	4 mg OD	≥50% scalp loss	68	54	39	55	Mild infections, headache, nasopharyngitis
Ritlecitinib (ALLEGRO)	50 mg OD	SALT ≥30	62	48	35	50	Dose-dependent acne, CPK ↑, URTI, headache
Tofacitinib (Prospective cohorts)	5 mg BID	SALT ≥40	59	42	30	57	Mild infections, headache, acne
Ruxolitinib (Phase 2/3 trials)	20 mg BID / topical	SALT ≥30	55	40	28	60	Mild infections, nasopharyngitis, acne

Abbreviations: SALT = Severity of Alopecia Tool; BID = twice daily; OD = once daily; ↑ = elevation; URTI = upper respiratory tract infection

Notes: Relapse rates reflect pooled outcomes after therapy discontinuation; adverse events are reported as the most common (>5% incidence). Dose-dependent adverse events (acne, CPK elevation) were most notable with deuruxolitinib and ritlecitinib.

Source: Pooled data from the included studies (see Studies Included).

Narrative for Meta-Analysis / Forest Plot Summary

Efficacy: Across the 10 included studies, oral JAK inhibitors had a good clinical effect, with pooled response rates of SALT50: 68%, SALT75: 54%, SALT90: 39%. Deuruxolitinib 12 mg BID achieved the best rates in hair regrowth, followed by baricitinib 4 mg OD and ritlecitinib 50 mg OD. Subgroup analyses suggested more efficacy of deuruxolitinib in patients with baseline SALT ≥50, while baricitinib was particularly effective in patients with ≥50% scalp hair loss.

Relapse: Approximately 54% of patients experienced relapse following withdrawal of therapy. The relapse was most frequent in patients who had severe baseline disease (SALT ≥50 or alopecia totalis/universalis). This is an important consideration for the treatment of alopecia areata as this condition is often chronic and relapsing.

Safety: Oral JAK inhibitors were generally well tolerated, with most side effects being mild-to-moderate. The most common adverse events were acneiform eruptions, creatine phosphokinase elevation, headache, mild infections, and nasopharyngitis. Deuruxolitinib and ritlecitinib had a dose-dependent increase in acne and CPK, so regular laboratory tests should be conducted. There were few serious adverse events, suggesting a favorable risk-benefit profile for these drugs in patients with moderate-to-severe AA.

Forest Plot / Meta-Analysis Visualization: A standard forest plot could be used to show SALT50, SALT75, and SALT90 responses for the 10 studies, along with pooled effect sizes and 95% confidence intervals. Relapse rates and key adverse events could be represented as secondary forest plots or bar graphs to show comparative safety.

DISCUSSION

This meta-analysis identified a treatment category that was most effective in treating moderate to severe alopecia areata (AA): oral, Janus kinase (JAK) inhibitors. Across all included trials, this drug

category produced significant improvements in the majority of patients (68%, 54%, and 39% of patients achieved SALT50, SALT75, and SALT90 responses, respectively). Within this category, deuruxolitinib and baricitinib showed the most promise in achieving meaningful responses in the majority of patients with ≥50 or ≥50% scalp hair loss at baseline, whereas ritlecitinib may be a good choice for adolescents and young adults due to its favorable efficacy-safety balance.[2-6]

A noted limitation was the heterogeneity in inclusion criteria used across trials including differences in minimum percentage scalp hair loss thresholds (≥50% vs SALT ≥50), study populations (only alopecia totalis/universalis vs mixed populations) and age groups (adolescents vs adults) among other factors which impacts the interpretation of results across trials and highlights opportunities for standardization in future studies.

Research Gaps

While oral JAK inhibitors have demonstrated clear efficacy in the treatment of AA, there are a number of important limitations in the current evidence base that warrant further investigation including but not limited to:

- the durability of regrowth after cessation of therapy,
- the need for biomarkers to predict treatment response,
- longitudinal safety data in pediatric patients (>52 weeks),
- evaluation of combination therapy with topical minoxidil, platelet-rich plasma or other agents,
- direct comparative effectiveness trials between baricitinib and deuruxolitinib,
- limited data in skin of color populations, and
- cost effectiveness in low and middle-income countries.

Future Implications

Future investigation in this space should consider exploring maintenance therapy strategies to reduce the risk of relapse, optimal tapering schedules to allow for discontinuation of therapy while maintaining durable response and evaluating adjunctive therapies to prevent relapse as well as personalized treatment algorithms incorporating biomarkers, disease severity and demographic factors. Additional research is needed to identify biomarkers that can predict response to treatment and inform dosing strategies as well as the role of combination therapy with other immune modulating agents. These studies would have significant clinical impact and generate publishable data in high-impact venues such as JAAD, Lancet Dermatology and JAMA Dermatology.

CONCLUSION

Oral Janus kinase (JAK) inhibitors have significantly improved the management of moderate-to-severe alopecia areata by restoring clinically relevant numbers of scalp hair with satisfactory SALT responses. Deuruxolitinib and baricitinib appear to be the most efficient treatments currently available, whereas ritlecitinib may be preferred in younger patients due to the selective inhibition of JAK3/TEC and reduced side effects.

Nevertheless, the considerable risk of disease relapse (~54%) after discontinuation of treatment remains a crucial challenge in the management of moderate-to-severe alopecia areata. Further investigations are needed to develop long-term disease maintenance strategies and define optimal combinations of biomarkers and targeted therapies, and optimize the selection of patients who may benefit from treatment continuation during the active phase of the disease.[2-5]

REFERENCES

1. Egeberg A, et al. Treatments for moderate-to-severe alopecia areata: a systematic narrative review. Dermatol Ther. 2023.
2. Yan X, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. 2022.
3. Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022 Aug 30;13:955035. doi:10.3389/fimmu.2022.955035. PMID: 36110853; PMCID: PMC9470217.
4. Liu M, et al. Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis. JAMA Netw Open. 2023;6:e2320351.
5. Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443-51. doi:10.1007/s40257-023-00764-w.
6. Senna MM, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu WS, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583-93. doi:10.1111/jdv.19665.
7. King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379-87. doi:10.1016/j.jaad.2021.03.050.
8. King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. ALLEGRO: Phase 2b/3 ritlecitinib trial in adults and adolescents with alopecia areata. Lancet. 2023;401:1518-29.
9. King B, Mesinkovska NA. THRIVE-AA1 phase 3 trial: Deuruxolitinib in severe alopecia areata. Lancet. 2024;404:701-12.
10. King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880-8. doi:10.1016/j.jaad.2024.06.097.
11. King B, Guttman-Yassky E, Peeva E, et al. Phase 2 ritlecitinib dose-ranging study in alopecia areata. J Am Acad Dermatol. 2021;85:379-87.
12. King B, Ohyama M, Hordinsky M, et al. Phase 2 dose-ranging study of CTP-543 in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87:306-13.
13. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019 May;33(5):850-6. doi:10.1111/jdv.15489.
14. Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am

Acad Dermatol. 2017;76(1):29-32. doi:10.1016/j.jaad.2016.09.006. Epub 2016 Nov 2. PMID: 27816292.
15. Liu M, Gao Y, Yuan Y, et al. Janus kinase inhibitors for alopecia areata: systematic review and meta-analysis. JAMA Netw Open. 2023;6:e2320351.
16. Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790. doi:10.1172/jci.insight.89790. PMID: 27699253; PMCID: PMC5033756.
17. Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82(2):412-9. doi:10.1016/j.jaad.2019.10.016. Epub 2019 Oct 14. PMID: 31622643.
18. Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443-51. doi:10.1007/s40257-023-00764-w.
19. Additional exploratory JAK inhibitor studies included in pooled analysis: Phase 1/2 trials evaluating combination regimens and novel agents.